U.S. regulatory status
CJC-1295
Also known as Modified GRF 1-29 · DAC:GRF · CJC-1295 DAC
Is CJC-1295 legal right now?
CJC-1295 is not FDA-approved for any use and has no drug-shortage or USP-monograph pathway. It previously appeared in Category 2 of the interim 503A bulks list but was removed around September 2024 after its nominations were withdrawn - which did not create a compounding pathway. At the December 4, 2024 advisory committee (PCAC) meeting, the committee voted against recommending it for the 503A list, citing insufficient efficacy and safety data. It is neither on the 503A list nor otherwise eligible, leaving its legal compounding status effectively unchanged.
In limbo: Nominated or removed from a restricted list but NOT approved - the headline implies a change, but the legal reality did not move.
Verified Jul 7, 2026 (ET) · status held since Dec 4, 2024
Where it sits in the process
- Nominated(stalled here - not advancing)
- Under review(not reached)
- Rulemaking(not reached)
- Compounding-legal(not reached)
Not on a path to the 503A list right now. The process stalled or reversed at this stage - read the status above. Sitting at an earlier step is not a sign it will advance.
What changed last
FDA advisory committee voted against adding CJC-1295 to the 503A list.
Status elsewhere
| Jurisdiction | Status | Note |
|---|---|---|
| United States (FDA) | In limbo | Removed from Category 2 (~Sept 2024); PCAC voted against inclusion Dec 4, 2024; not on the 503A list; no USP monograph. |
| United Kingdom (MHRA) | Restricted | No UK marketing authorisation; supply for human use treated as an unlicensed medicine. |
| Australia (TGA) | Restricted | Reported as Schedule 4 (prescription-only) under the Poisons Standard. |
| Sport / anti-doping (WADA) | Restricted | Prohibited at all times under S2 as a growth-hormone-releasing factor analogue. |
Sources & transparency
Sources for this entry
- Federal Register - PCAC notice of meeting, Dec 4, 2024 Federal Register · primaryConfirms the Dec 4, 2024 PCAC meeting on nominated 503A bulk substances.
- On Healthcare - The Category 2 peptide unwind analysisRemoved from Category 2 (~Sept 20, 2024); PCAC voted against inclusion Dec 4, 2024.
- BSCG - CJC-1295 in sport analysisProhibited at all times under WADA S2; not FDA-approved.
- Last verified by a human
- Jul 7, 2026 (ET) · how we verify
- Who runs this
- Peptlas Research Team - independent. About us.
- What we sell
- Nothing. No products, no affiliates, no sponsored placements.
- Confidence
- medium - some facts here rest on secondary reporting. Always confirm against the primary source before you rely on it.
This page reports publicly available regulatory status for information only. It isnot medical or legal advice and makes no health claim. See ourfull disclaimer.
Get alerted when CJC-1295's status changes
We'll email you only when this entry's official status moves - and never anything else.